Article
Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Clinical lung cancer - 1 Jan 2014
Metro Giulio, Chiari Rita, Bennati Chiara, Cenci Matteo, Ricciuti Biagio, Puma Francesco, Flacco Antonella, Rebonato Alberto, Giannarelli Diana, Ludovini Vienna, Bellezza Guido, Ferolla Piero, Minotti Vincenzo, Crinò Lucio
Abstract excerpt
BACKGROUND: We hypothesized that KRAS mutations function as a marker of poor sensitivity to first-line platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type (WT) non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Consecutive advanced nonsquamous EGFR WT NSCLCs treated at the Medical Oncology of Perugia with simultaneous assessment of KRAS mutation status were eligible. Anaplastic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.